MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Companies

King's College London Business Ltd

King's College London Business Ltd
King's College London Business Ltd is responsible for commercialisation of technologies emanating from King's. Opportunities include: Collaborative & Contract research, Consultancy, Clinical trials.

The company in detail

Profile

King’s College London has a history of excellence in generating and improving new innovative technologies from research for patient benefit and wealth creation. The disciplines of Medicine, Dentistry, Psychiatry, Biomedical & Health Sciences and Nursing & Midwifery invested a combined £220 million in research in the year 2007-8.

King’s works closely as an academic partner with three NHS foundation trusts: Guy’s and St Thomas’; King’s College Hospital, and the South London and Maudsley. The College and the NHS trusts already work closely in all three types of National Institute for Health Research (NIHR) research centres, including a Comprehensive Biomedical Research Centre: one of only five such centres in the UK. King’s is the only university to be an academic partner in all three categories of research centre. Our NHS partner Trusts serve around 60 per cent of London’s population (some five million people), giving the academic-clinical partnership unique opportunities to translate ground-breaking research into direct patient benefits for a large and diverse population. This successful partnership has recently been formally accredited as King’s Health Partners, www.kingshealthpartners.org, one of the UK’s first Academic Health Sciences Centres (AHSCs). King’s also hosts six prestigious Medical Research Council (MRC) Centres, more than any other institution.

Combined with this access to the clinical environment, our wealth of multidisciplinary expertise offers partner companies access to a critical mass of integrated research and key opinion leaders in the development and clinical application of new technologies. Working closely with industry is pivotal to the success of our mission to drive pioneering technologies to market and create healthcare solutions that will improve the lives of patients. 

 

Partnering strategy/interests

King’s College London is one of the world’s top 22 universities (2008Times Higher-QS World University Rankings) and is in the top group of UK universities for research earnings. A multi-faculty, research-led university based in the heart of London, it has a strong commitment to supporting the knowledge economy and through King's College London Business, www.kcl.ac.uk/business offers a range of excellent research and commercial opportunities for business and the wider community. This activity is a key part of achieving the College’s mission to translate its ideas, research and skills into innovative new products and services that are of real commercial value.

Out-licensing

A simple blood based assay to identify diabetic patients who are likely to develop or have early stage diabetic nephropathy has been developed at King's. This has the potential to be used regularly at diabetic clinics. More
A novel adjuvant technology for use in vaccines and in antibody production that gives excellent immune responses with low manufacturing costs, and can be administered by a variety of routes More
The measurement of GSK-3 in circulating white cells is a useful early diagnostic marker and potential therapy for Alzheimer's Disease. More
The first functional test for simultaneous identification and validation of miRNA targets, which is easy to use and offers rapid results with guaranteed accuracy. More
Easy detection of haemoglobinopathies through use of MSMS. More
Hybridomas (5 clones) expressing antibodies to human immunodeficiency virus type 1 More
Hybridomas (2 clones) expressing antibodies to human immunodeficiency virus type 1 More
Hybridomas (2 clones) expressing antibodies to human immunodeficiency virus type 1 More
Hybridomas (2 clones) expressing antibodies to human immunodeficiency virus type 1 More
Reversible, non-hormonal, oral delivery approach to male contraception More
Mammalian lactase gene constructs for use as autologous mammalian lactase gene constructs for use as autologous β-galactosidase reporter genes More
Novel cloning technology for rapid recombinant antibody production. More
Applications in targeting Tumour Invasiveness & Respiratory Conditions More
A comprehensive database of over 12,000 constituents from over 300 Chinese herbs incorporating all available chemical, botanical, and biological activity data More

Deals

To view this information, you must subscribe to PL Intelligence.

Press Releases

(28th Jul 2009) Research into neurodegenerative disease at the Institute of Psychiatry has resulted in the development of a series of biomarkers, or tests, for Alzheimer’s disease. More
(8th Jun 2009) Proximagen, a King’s College London spin-out company focusing on neurodegenerative diseases, has raised £50 million in one of the largest biotech fundraisings in the UK in the past ten years. More
(26th May 2009) Figures just published confirm King’s College London’s position as one of the UK’s top research-led universities. The College is the most successful higher education institution in winning grants from the Department of Health. More
(10th Mar 2009) OSspray prepares for market launch More
(21st Oct 2008) King's College London and Royal Philips Electronics More
(1st Sep 2008) Dr Alistair Noble from the MRC & Asthma UK Centre in Allergic Mechanisms of Asthma at King’s, has developed a new technology for vaccine development which could be used for a variety of diseases such as Asthma, Tuberculosis, HIV and influenza. More
More press releases

Contact details

Dr Mike Shaw
Director of Technology Transfer

Contact directly

Full contact list

Head office

King's College London Business Ltd
8th Floor, Capital House
42 Weston Street
London
SE1 3QD
United Kingdom

Company figures

Number of employees: 5000

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us